Vericel beats Q2 revenue estimates, boosts annual outlook

Vericel

30/07/2026 13:06

Overview
US advanced therapies firm's Q2 revenue rose 22%, beating analyst expectations
Net income reached $2.2 mln, reversing a loss from prior year
Company raised full-year 2026 revenue guidance and authorized $200 mln share buyback

Outlook
Vericel raises 2026 total revenue guidance to $330-$340 mln from $326-$336 mln
Company expects 2026 MACI revenue of $284-$290 mln, up from prior $282-$288 mln
Vericel maintains 2026 gross margin guidance at about 75% and adj EBITDA margin at about 27%

Result Drivers
MACI GROWTH - Company said MACI revenue rose 23% in Q2, with double-digit growth in biopsies and implants
BURN CARE PRODUCTS - Burn care net revenue increased 22%, with record NexoBrid quarterly revenue and 21% growth in Epicel
SALES FORCE AND MARKETING - Higher operating expenses were mainly due to increased headcount and expanded marketing programs

Company press release: ID:nGNX3bSCM2

Key Details
Metric
Beat/Miss
Actual
Consensus Estimate
Q2 Revenue
Beat
$77.46 mln
$72.69 mln (8 Analysts)
Q2 EPS
 
$0.04
 
Q2 Net Income
 
$2.21 mln
 
Q2 Adjusted EBITDA
 
$14.86 mln
 
Q2 Gross Margin
 
73.00%
 
Q2 Adjusted EBITDA Margin
 
19.00%
 
Q2 Gross Profit
 
$56.40 mln
 

Analyst Coverage
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 7 "strong buy" or "buy", 1 "hold" and no "sell" or "strong sell"
The average consensus recommendation for the pharmaceuticals peer group is "buy"
Wall Street's median 12-month price target for Vericel Corp is $55.00, about 18% above its July 29 closing price of $46.62
The stock recently traded at 68 times the next 12-month earnings vs. a P/E of 62 three months ago

Reuters Recommended Reads
July 29 - Anika Therapeutics Q2 revenue rises, lifts 2026 outlook
July 29 - MiMedx Q2 sales fall less than expected; set to acquire Sanara MedTech
July 29 - AxoGen Q2 revenue beats estimates on breast procedure growth

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)